Suggested remit: To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.
Status In progress
Process STA 2018
ID number 3735

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
04 May 2020 - 03 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
06 February 2020 In progress. Topic is now in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance